Table 3.
An outline of clinical trials following combination approaches in lung cancer patients.
| Drug Combination | Phases/Study | Treatment Outcome | References |
|---|---|---|---|
| Platinum + pemetrexed + pembrolizumab | Phase III (Keynote 189) | median OS—22.0 months; median PFS—9.0 months |
[256] |
| Carboplatin + (nab)-paclitaxel + pembrolizumab | Phase III (Keynote 407) | median OS—15.9 months; median PFS—6.4 month |
[257] |
| Carboplatin + nab-paclitaxel + atezolizumab | Phase III (Impower 130) | median OS—18.6 months; median PFS—7.0 months |
[258] |
| Carboplatin + paclitaxel + bevacizumab + atezolizumab | Phase III (Impower 150) | median OS—19.2; median PFS—8.3 months |
[253] |
| Pembrolizumab + platinum + pemetrexed | Phase III | median OS—12 months; median PFS—8.8 months | [255] |
| Nivolumab + ipilimumab + two cycles of chemotherapy | Phase III (CheckMate 9LA) | median OS—15.6 months; | [259] |
| Avelumab + axitinib | Phase II (Javelin Medley VEGF) | ORR—31.7%; median PFS—5.5 months | [260] |
| Nivolumab + ipilimumab | Phase III (CheckMate 227) | median OS—17.1 months | [261] |
| Pembrolizumab + stereotactic body radiation therapy (SBRT) | Phase II (PEMBRO-RT) | median OS—15.9 months; median PFS—6.6 months | [262] |
Abbreviations: OS—overall survival; PFS—progression-free survival; ORR—objective response rate.